(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Tvardi Therapeutics's earnings in 2026 is -$13,945,000.On average, 10 Wall Street analysts forecast TVRD's earnings for 2026 to be -$19,671,740, with the lowest TVRD earnings forecast at -$29,052,146, and the highest TVRD earnings forecast at -$13,790,576. On average, 9 Wall Street analysts forecast TVRD's earnings for 2027 to be -$33,976,414, with the lowest TVRD earnings forecast at -$76,767,538, and the highest TVRD earnings forecast at -$12,116,006.
In 2028, TVRD is forecast to generate -$28,496,771 in earnings, with the lowest earnings forecast at -$59,299,475 and the highest earnings forecast at -$3,447,644.